Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD9291 (Osimertinib) in EGFR T790M+ NSCLC Detected by Plasma ctDNA
NCT02811354Phase 2Unknown
- Sponsor
- National University Hospital
- Start
- Feb 2017
- Primary completion
- Feb 2019
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 2, open-label, single-arm trial of osimertinib in non-small cell lung cancer (NSCLC), sponsored by National University Hospital. Primary endpoint: Objective Response Rate. Status: unknown.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02811354.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02811354.